Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

Bennett-Guerrero, 2021
 
NCT04344535
RCTconvalescent plasma treatmentplaceboCOVID 19 hospitalizedsome concern
59/15 inconclusive
    RECOVERY (plasma), 2021
     
    NCT04381936
    RCTconvalescent plasma treatmentcontrolCOVID 19 hospitalizedsome concern
    5795/5763 inconclusive
    • inconclusive 0 % increase in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
    ConCOVID (Gharbharan et al.), 2020
     
    NCT04342182
    RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedsome concern
    43/43 inconclusive
    • inconclusive 5 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
    ConPlas-19, 2020
     
    NCT04345523
    RCTconvalescent plasma treatmentstandard of careCOVID 19 hospitalizedsome concern
    38/43 inconclusive
    • inconclusive 92 % decrease in death or ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
    Abolghasemi, 2020
     
    IRCT20200325046860N1
    OBSconvalescent plasma treatmentcontrolCOVID 19 hospitalizedcritical
    115/74 inconclusive

      COVID-19 mild to moderate meta-analysis

      Libster, 2020
       
      NCT04479163
      RCTconvalescent plasma treatmentplaceboCOVID-19 mild to moderatelow
      80/80 conclusif
      • demonstrated 48 % decrease in clinical deterioration (PE) with a high degree of certainty due to low risk of bias
      PLACID, 2020
       
      CTRI/2020/04/024775
      RCTconvalescent plasma treatmentstandard of careCOVID-19 mild to moderatehigh
      235/229 suggested
      • inconclusive 7 % increase in death or transfer to ICU (PE) but with a low degree of certainty due to high risk of bias
      • suggested 20 % increase in viral clearance by day 7 but with a low degree of certainty due to high risk of bias

      COVID-19 severe or critically meta-analysis

      O’Donnell, 2021
       
      NCT04359810
      RCTconvalescent plasma treatmentplaceboCOVID-19 severe or criticallylow
      150/73 inconclusive
      • inconclusive 38 % increase in clinical improvement (28-day) (PE) with a high degree of certainty due to low risk of bias
      AlQahtani, 2020
       
      NCT04356534
      RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
      20/20 inconclusive
      • inconclusive 33 % decrease in mechanical ventilation (PE) with a moderate degree of certainty due to some concern in risk of bias
      ILBS-COVID-02 (Bajpai M), 2020
       
      NCT04346446
      RCTconvalescent plasma treatmentcontrolCOVID-19 severe or criticallyhigh
      14/15 inconclusive
      • inconclusive 74 % decrease in off oxygenation (PE) but with a low degree of certainty due to high risk of bias
      Li, 2020
       
      ChiCTR2000029757
      RCTconvalescent plasma treatmentstandard of careCOVID-19 severe or criticallysome concern
      52/51 inconclusive
      • inconclusive 40 % increase in clinical improvement,clinical improvement (time to event analysis only) (PE) with a moderate degree of certainty due to some concern in risk of bias
      PICP19 (Ray), 2020
       
      CTRI/2020/05/025209
      RCTconvalescent plasma treatmentcontrolCOVID-19 severe or critically
      bias due to deviations from intended interventions some concern
      bias due to missing outcome data low
      bias in measurement of the primary outcome low
      bias in selection of the reported result high
      " >high
      40/40 inconclusive PlasmAr, 2020
       
      NCT04344535 RCTconvalescent plasma treatmentcontrolCOVID-19 severe or criticallylow
      228/106 inconclusive PlasmAr, 2020
       
      NCT04344535 RCTconvalescent plasma treatmentplaceboCOVID-19 severe or criticallylow
      228/106 inconclusive Rasheed, 2020 RCTconvalescent plasma treatmentcontrolCOVID-19 severe or criticallyNA
      21/28 inconclusive Duan, 2020 OBSconvalescent plasma treatmentcontrolCOVID-19 severe or criticallycritical
      10/10 inconclusive Hegerova, 2020 OBSconvalescent plasma treatmentcontrolCOVID-19 severe or criticallycritical
      20/20 inconclusive Sean, 2020 OBSconvalescent plasma treatmentcontrolCOVID-19 severe or criticallycritical
      39/156 inconclusive Joyner, 2020
       
      NCT04338360 NRaconvalescent plasma treatmentconvalescent plasma treatmentCOVID-19 severe or criticallyserious
      515/561 inconclusive

      PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
      Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).